Liquid Biopsy

Liquid Biopsy

Global Liquid Biopsy Market to Reach US$17.1 Billion by 2030

The global market for Liquid Biopsy estimated at US$5.4 Billion in the year 2023, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2023-2030. Multi Gene Parallel Analysis Technology, one of the segments analyzed in the report, is expected to record a 18.1% CAGR and reach US$12.1 Billion by the end of the analysis period. Growth in the Single Gene Analysis Technology segment is estimated at 17.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 17.1% CAGR

The Liquid Biopsy market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 17.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.1% CAGR.

Global Liquid Biopsy Market - Key Trends & Drivers Summarized

Why Is Liquid Biopsy Revolutionizing Cancer Diagnosis and Treatment?

Liquid biopsy is revolutionizing the field of cancer diagnosis and treatment by offering a non-invasive, accurate, and real-time method to detect and monitor cancer. Unlike traditional tissue biopsies, which require surgical procedures to obtain samples, liquid biopsies involve analyzing a blood sample to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), or other biomarkers associated with cancer. This approach allows for the early detection of cancer, monitoring of disease progression, and assessment of treatment efficacy, all with minimal discomfort to the patient. The ability of liquid biopsies to provide comprehensive insights into the genetic makeup of tumors is transforming personalized medicine, enabling oncologists to tailor treatments to individual patients` needs more effectively. As the demand for less invasive, more accurate diagnostic tools grows, liquid biopsy is rapidly gaining acceptance as a valuable tool in oncology.

How Are Technological Advancements Driving the Liquid Biopsy Market?

Technological advancements are playing a crucial role in driving the growth and adoption of liquid biopsy, making it more accurate, accessible, and informative. Innovations in next-generation sequencing (NGS) and digital PCR (Polymerase Chain Reaction) technologies are enhancing the sensitivity and specificity of liquid biopsies, allowing for the detection of minute amounts of cancer-related biomarkers in the blood. These advancements are enabling the identification of a broader range of genetic mutations, providing deeper insights into tumor biology and treatment response. Additionally, the development of advanced bioinformatics tools is improving the analysis and interpretation of liquid biopsy data, facilitating more precise and personalized treatment decisions. The ongoing refinement of liquid biopsy assays is also expanding their application beyond oncology, with potential uses in monitoring organ transplant rejection, detecting infectious diseases, and assessing prenatal genetic conditions. These technological innovations are making liquid biopsy a more powerful and versatile tool in precision medicine.

What Market Trends Are Shaping the Demand for Liquid Biopsy?

Several key market trends are shaping the demand for liquid biopsy, including the increasing emphasis on personalized medicine, the growing adoption of non-invasive diagnostic tools, and the expansion of liquid biopsy applications beyond oncology. As personalized medicine continues to gain traction, there is a growing need for diagnostic tools that can provide detailed genetic information to guide targeted therapies. Liquid biopsy`s ability to offer real-time insights into tumor genetics makes it a valuable asset in this approach. The trend towards non-invasive diagnostics is also driving demand for liquid biopsy, as patients and healthcare providers seek less invasive, more comfortable alternatives to traditional tissue biopsies. Additionally, the potential for liquid biopsy to be used in other areas of medicine, such as transplant monitoring and infectious disease detection, is expanding its market opportunities. The increasing use of liquid biopsy in clinical trials and drug development is further contributing to its growth, as it provides a valuable tool for monitoring treatment response and disease progression in real-time.

What Is Driving the Growth in the Liquid Biopsy Market?

The growth in the liquid biopsy market is driven by several factors. The rising incidence of cancer worldwide and the growing demand for less invasive diagnostic methods are major drivers, as liquid biopsy offers a more patient-friendly alternative to traditional biopsies. Technological advancements in genomics and molecular diagnostics are enhancing the accuracy and utility of liquid biopsy, making it a more attractive option for both clinicians and patients. The increasing adoption of personalized medicine and the need for real-time monitoring of cancer progression and treatment response are also contributing to the market`s expansion. Additionally, the broadening of liquid biopsy applications beyond oncology, such as in transplant monitoring and prenatal testing, is creating new opportunities for growth. The growing number of clinical trials and research studies utilizing liquid biopsy is further supporting market development, as these efforts continue to validate and expand the potential uses of this innovative technology.

Select Competitors (Total 42 Featured) -

• Apostle Inc
• Biocept, Inc.
• BioChain Institute, Inc.
• Biolidics Ltd.
• CatchGene
• Elphogene
• F. Hoffmann-La Roche AG
• Gencurix, Inc.
• Genomill Health
• Guardant Health, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.